All News

Nurse_0.jpg

Patients Prefer Nurse Led Care for their Gout

d Jack Cush, MD

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level 6 mg/dl, this goal is seldom achieved ( 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.

Read Article
gastric.jpg

Voluntary Recall of Zantac by Sanofi/FDA

d Jack Cush, MD

Sanofi has initiated a voluntary recall of all Zantac OTC (over-the-counter) products in the United States. This includes Zantac 150®, Zantac 150® Cool Mint, and Zantac 75®.

Read Article
FDA%20approved2.jpg

FDA Approves Ustekinumab for Ulcerative Colitis

d Jack Cush, MD

Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.

Read Article
joint.pain_.hand_.PIP_.jpg

Pain Persists Despite TNF Inhibitor Use

d Jack Cush, MD

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain.

Read Article
preg.hands_.jpg

Adalimumab and Pregnancy Outcomes

d Jack Cush, MD

A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increase

Read Article
bone.infection.gram_.rod_.jpg

Interleukin Targeted Biologics Increase Risks of Infection

d Jack Cush, MD

A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.

Read Article
ra.hands2_.JPG

Comorbidities Increase in Importance in RA

d RheumNow

Patients with rheumatoid arthritis (RA) have a large comorbidity burden at the time of diagnosis, including a wide range of ailments but with pulmonary disease a particular concern, a U.K. population-based study found.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Fight or Switching (DMARDs) (10.18.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
joint.injx_.jpg

Joint Injections: Are They Worth the Risk?

d RheumNow

Intra-articular injections of corticosteroids for relief of the pain of hip or knee osteoarthritis (OA) may have adverse long-term consequences, researchers suggested.

Read Article
#RA study shows that from 2014 to 2018, the number of malignant tumors that could be treated with immune checkpoint inhibitors has grown from 0 to 7%. Knowledge of ICI immune related adverse events is essential for rheumatologists https://t.co/bwRYRBl4PE

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study of 102 RA patients interstitial lung dz, and 52% had progressive fibrosing-ILD; these were associated with increased mortality. Predictors of mortality were DLco and high titres https://t.co/Ydd9xAhsag IgM rheumatoid factor

Links:

Dr. John Cush RheumNow ( View Tweet)

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended marketing authorization for upadacitinib (Rinvoq) for the treatment of rheumatoid arthritis #RA. https://t.co/xnun9oiO9q

Links:

Dr. John Cush RheumNow ( View Tweet)

THe European Medicines Agency committee announced a positive opinion recommending romosozumab for the treatment of severe osteoporosis in postmenopausal women at high Fracture risk for fracture w/ no hx of MI/CVA https://t.co/sr7iPaSngj

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! The week in review - Watch it here>> https://t.co/c0EPyvKNWD or listen to the podcast in your car (Android Auto, Apple Car play) or here>> https://t.co/xZWQTszGn9

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! The week in review - on statins, Comorbidities, ANA specificity, APL Ab effects, PsA surgery & more. Watch it here>> https://t.co/c0EPyvKNWD or listen to the podcast in your car (Android Auto, Apple Car play) or here>> https://t.co/xZWQTszGn9

Links:

Dr. John Cush RheumNow ( View Tweet)

Risk of uveitis in JIA - study 2294 JIA pts in the UK JIA registries finds that uveitis occured in 27/943 MTX, 16/1047, and only 1 of 304 adalimumab/infliximab Rx pts. No difference w/ MTX & etanercept, but much less with adalimumab https://t.co/rO13LznMmm

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow survey for Rheumatologists – When treating GCA, when do you add a steroid sparing agent? https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of RA complications from National Inpatient Sample data (2005-14) show #RA higher risk for MI (OR 1.03), COPD (1.67), CVA ( 2.2), renal Dz (1.42), EtOH abuse (2.73). Mortality trend increased significantly for CHF (P = 0.025) & AFib (P = 0.042) https://t.co/NzKPWsyKgA

Links:

Dr. John Cush RheumNow ( View Tweet)

RHEUMATOLOGISTS - In what percentage of your GCA patients do you use a steroid-sparing agent? Few, Some, Many? RHEUMNOW Live Vote: Rheums Click here>> https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM Case: 4-year-old girl with juvenile dermatomyositis refractory to multiple therapies has active rash, weakness & extensive calcification and strongly positive for anti–NXP-2 . Improved w/ infliximab, thalidomide, aluminum hydroxide. https://t.co/Wbb6JEMtrh

Links:

Dr. John Cush RheumNow ( View Tweet)

×